A Randomised, Single Dose, 5-period, 5-treatment, Crossover Study to Assess the Relative Bioavailability of 4 Different Formulations of Verinurad and Allopurinol in Healthy Subjects
Latest Information Update: 12 May 2023
Price :
$35 *
At a glance
- Drugs Allopurinol/verinurad (Primary) ; Verinurad (Primary) ; Oxipurinol
- Indications Renal failure
- Focus Pharmacokinetics
- Sponsors AstraZeneca
- 20 Jul 2021 Status changed from active, no longer recruiting to completed.
- 29 Jun 2021 Status changed from recruiting to active, no longer recruiting.
- 23 Apr 2021 Status changed from not yet recruiting to recruiting.